Baricitinib

Baricitinib
Clinical data
Trade names	Olumiant, others
Other names	INCB28050, LY3009104
AHFS/Drugs.com	Monograph
MedlinePlus	a618033
License data	US DailyMed: Baricitinib;
Pregnancy; category	AU: D; Use is contraindicated;
Routes of; administration	By mouth
ATC code	L04AF02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	79%
Protein binding	50%
Metabolism	CYP3A4 (<10%)
Elimination half-life	12.5 hours
Excretion	75% urine, 20% faeces
Identifiers
	IUPAC name 2-[1-Ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile;
CAS Number	1187594-09-7;
PubChem CID	44205240;
DrugBank	DB11817;
ChemSpider	26373084;
UNII	ISP4442I3Y;
KEGG	D10308;
ChEBI	CHEBI:95341;
ChEMBL	ChEMBL2105759;
PDB ligand	3JW (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID30152228 ;
ECHA InfoCard	100.219.080
Chemical and physical data
Formula	C16H17N7O2S
Molar mass	371.42 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1;
	InChI InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20); Key:XUZMWHLSFXCVMG-UHFFFAOYSA-N;

Baricitinib, sold under the brand name Olumiant among others, is an immunomodulatory medication used for the treatment of rheumatoid arthritis, alopecia areata, and COVID-19. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.

Baricitinib is approved for medical use in the European Union and in the United States.